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Background: The majority of sentinel node (SN) positive breast cancer patients do not have
additional non-SN involvement and may not beneﬁt from axillary lymph node dissection
(ALND). Previous studies in melanoma have suggested that microanatomic localization of SN
metastases may predict non-SN involvement. The present study was designed to assess whe-
ther these criteria might also be used to be more restrictive in selecting breast cancer patients
who would beneﬁt from an ALND.
Methods: A consecutive series of 357 patients with invasive breast cancer and a tumor-
positive axillary SN, followed by an ALND, was reviewed. Microanatomic SN tumor features
(subcapsular, combined subcapsular and parenchymal, parenchymal, extensive localization,
multifocality, and the penetrative depth from the SN capsule) were evaluated for their pre-
dictive value for non-SN involvement.
Results: Non-SN metastases were found in 136/357 cases (38%). Microanatomic location
and penetrative depth of SN metastases were signiﬁcant predictors for non-SN involvement
(<0.001); limited penetrative depth was associated with a low frequency of non-SN
involvement with a minimal of 10%.
Conclusions: Microanatomic location and penetrative depth of breast cancer SN metastases
predict non-SN involvement. However, based on these features no subgroup of patients could
be selected with less than 10% non-SN involvement.
Key Words: Breast cancer—Sentinel node—Axillary lymph node metastases—Morphometry.
Axillary nodal status is among the most important
prognostic factors in breast cancer patients. SN
biopsy with an intensive pathological assessment of
selectively removed lymph nodes is currently a highly
accurate, minimally invasive technique to assess no-
dal status.
1,2 It reduces the morbidity of breast cancer
surgery by avoiding unnecessary axillary lymph node
dissection (ALND) in patients with negative sentinel
nodes (SNs).
3 The optimal treatment of patients with
a positive SN is however less clear. The few SNs can
be cost-effectively analyzed by multiple-level evalua-
tion and immunohistochemistry (IHC) which in-
creases the likelihood of detecting small metastases.
4
The decision to proceed with an ALND in patients
with macrometastatic SN involvement does not pose
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1309a major clinical dilemma. The need for routine
ALND in patients with minimal SN involvement
however continues to be debated since only a
minority of these patients (10–15%) show non-SN
involvement.
5 Predicting the chance of involvement
of the non-SN would facilitate the selection of pa-
tients with a potential therapeutic beneﬁt of ALND.
Several features of the primary tumor and the in-
volved SNs have been investigated as potential pre-
dictors for non-SN involvement. Primary tumor size,
palpability, presence of peritumoral lymphovascular
invasion, number of tumor-involved SNs, size of the
SN metastases, and extracapsular extension (ECE)
correlate with non-SN status.
6–10 However, none of
these factors are sensitive and reproducible enough to
reliably identify a subgroup of patients who might be
spared ALND.
Several melanoma studies have reported that the
microanatomic pattern of SN involvement and the
penetrative depth (deﬁned as the maximum distance
of cancer cells from the inner margin of the SN
capsule) predict non-SN involvement.
11–14 In breast
cancer, this has been studied less extensively.
15We
therefore set out to study the predictive value of
microanatomic location and penetrative depth of SN
metastatic deposits for non-SN metastases, accu-
rately assessed by morphometry, in a large series of
SN-positive breast cancer patients.
PATIENTS AND METHODS
Patients
A retrospective database was analyzed, including
patients with invasive breast cancer and a tumor
positive axillary SN followed by ALND, treated at
the University Medical Center Utrecht or the St
Antonius Hospital in Nieuwegein from January 2000
to May 2007 (n = 357), including patients from our
previous study.
16 Exclusion criteria were multicentric
tumors, neoadjuvant chemotherapy, and a total of
fewer than six lymph nodes examined.
SN Biopsy Technique
The technical aspects used for the SN procedure
are described in detail elsewhere.
16 Brieﬂy, before
surgery, SN identiﬁcation was performed by peritu-
moral injection of 120 MBq
99mTc-Nanocolloid
(Amersham Cygne, Eindhoven, The Netherlands) in
a maximal volume of 0.5 mL. Dynamic and static
scintigraphic images were subsequently obtained. On
the same day, immediately preoperatively 0.5 mL
Patent blue dye (Guerbet, Aulnay-sous-Bois, France)
was injected intradermally and intra/peritumorally.
The SN was identiﬁed after careful dissection of blue
lymphatic channels and detection of radioactivity
with a handheld gamma ray detection probe. Palpa-
tion of the open axilla was performed to detect en-
larged non-SN metastases.
Histopathological Evaluation
The SNs were processed according to the protocols
described previously.
16–18 SNs were lamellated
according to their size, ﬁxed in neutral buffered
formaldehyde, and completely embedded. Step sec-
tions 5 lm thick were cut at ﬁve levels with 250 lm
intervals for staining with haematoxylin and eosin
(H&E). In the absence of apparent metastases by
H&E examination, immunohistochemistry was per-
formed with CAM 5.2 (Beckton Dickinson, Franklin
Lakes, New Jersey, USA) or CK AE1/3 (Dako,
Glostrup, Denmark) at each level. All non-SNs were
identiﬁed visually or by palpation, dissected, pro-
cessed routinely, and examined at one level with H&E
staining. All SNs and non-SNs were examined ini-
tially by multiple pathologists at the two institutions,
reviewed histologically, and reclassiﬁed according to
the current 6
th edition of the American Joint Com-
mittee on Cancer (AJCC) staging system by one ob-
server (CHMvD). All cases were evaluated without
knowledge of non-SN involvement.
Clinicopathological Features
Clinicopathological features recorded included age,
pT (TNM system of the AJCC), histological subtype
(according to the WHO), histological grade (deﬁned
according to the Nottingham modiﬁed Bloom–
Richardson score based on the percentage of tubule
formation, nuclear pleomorphism and mitotic activ-
ity), mitotic activity index (MAI),
19 steroid receptor
and HER-2/neu status (not routinely determined be-
fore 2005).
SN and Non-SN Characteristics
SN characteristics included metastatic size
according to the 6
th edition of the AJCC staging
system [isolated tumor cells (ITC) (£0.2 mm), mi-
crometastases (>0.2 mm and £2 mm), macrometas-
tases (>2 mm)], the number of SNs, ECE, maximal
diameter of the largest metastases, microanatomic
location of the metastatic deposit, and the penetrative
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in the same SN, the largest metastasis was recorded.
If single tumor cells, cluster of nests were continuous,
or separated by a few cells distance, they were mea-
sured as one focus.
20 If more than one SN was in-
volved in an individual patient, the most extensive
and/or deepest metastatic deposit was recorded. In
case both axillary and internal mammary SNs were
involved, the features were measured in the axillary
SN.
The microanatomic location of metastatic deposits
within each SN was classiﬁed as subcapsular, com-
bined subcapsular and parenchymal, parenchymal or
extensive. Extensive SN involvement, as deﬁned in the
study of Ruiter et al.,
21 was a deposit >5 mm in
diameter (Fig. 1). The centripetal depth was, accord-
ing to Starz et al.,
11 deﬁned as the maximal depth at
which tumor cells have inﬁltrated the SN, as measured
from the inner margin of the capsule (Fig. 2), further
denoted tumor penetrative depth according to the pro-
posal of Scolyer et al.
12 Multifocality was deﬁned as
two or more separated metastatic deposits at some
distance from each other. All measurements were cal-
culated microscopically in the plane of the tissue sec-
tionsusinginteractivevideomorphometrysystems(Q-
PRODIT, Leica, Cambridge, UK or Research Video
Assistant, Baarn, The Netherlands).
Non-SN characteristics included the total number
of non-SNs, maximal tumor diameter, AJCC classi-
ﬁcation, and ECE. If more than one non-SN was
involved, the largest diameter was recorded.
Statistical Analysis
Statistical analysis was performed using SPSS 13.0
for Windows. Patients were divided into groups with
and without non-SN involvement. The Pearson chi-
square test was used to determine the relationship
between categorical variables (histological type and
grade, steroid receptor and HER-2/neu status, num-
ber of SNs, AJCC classiﬁcation, ECE) on the one
hand and non-SN status on the other. Continuous
data (age, diameter primary tumor, MAI, SN tumor
diameter) were analyzed using the Mann–Whitney U-
test. P-values <0.05 were considered signiﬁcant. All
relevant variables that were associated with the
presence of positive non-SNs were included in a
multivariate logistic regression model. SN metastatic
characteristics (diameter and penetrative depth) were
further compared by receiver operating characteristic
(ROC) analysis, calculating the area under curve
(AUC) as a measure of discriminative value.
RESULTS
The median age was 53 years (range 22–86 years)
and the mean histological invasive tumor size was
2.4 cm (range 0.3–9.0 cm). Overall, 571 SNs were
obtained (mean 1.6 SN per patient) of the 357 pa-
tients with a positive SN as well as 4939 non-SNs
(mean 14 per patient). The metastatic deposits were
subcapsular in 167 patients (47%), combined sub-
capsular and parenchymal in 40 patients (11%),
parenchymal in 11 patients (3%), and extensive in
139 patients (39%) (Fig. 1). Of the 357 patients, 24
(7%) patients had ITC only in the SN, whereas 112
(31%) had micrometastases and 221 (62%) had ma-
crometastases. Localisation of ITCs was subcapsular
(96%) or parenchymal (4%). SN micrometastases
were located subcapsularly (81%), parenchymally
(5%) or had combined localisation (13%). The
overall prevalence of non-SN involvement was 38%
(136/357 patients). Other descriptive characteristics
of the study population are listed in Tables 1 and 2.
FIG. 1. Pattern of distribution of metastatic breast cancer deposits
in SNs.
FIG. 2. The tumor penetrative depth of metastases was deﬁned as
the maximal distance of breast cancer cells from the inner margin
of the SN capsule (arrow) (H&E, original magniﬁcation · 10).
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non-SN metastases by univariate analysis: primary
tumor size, number of involved SNs, ECE, AJCC
classiﬁcation, diameter, and penetrative depth of the
TABLE 1. Clinicopathological characteristics of 357 inva-
sive breast cancer patients with a positive SN and subsequent
axillary lymph node dissection
Feature No. %
Mean age (range) 54 y (22–86)
Primary tumor
Mean tumor size (range) 2.4 cm (0.3–9.0)
pT1 187 52
pT2 150 42
pT3 19 5
pTx 1 0
Histological subtype
Invasive ductal cancer 298 84
Invasive lobular cancer 36 10
Others 23 6
Histological grade (B&R)
17 4 2 1
2 161 45
3 122 34
MAI, mean/2 mm
2 (range) 13 (0–102)
Steroid receptor status
ER – positive  322 90
ER – negative 34 10
ER – unknown 1
PR – positive  284 80
PR – negative 70 20
PR – unknown 3
HER-2/neu status
Positive 26 15
Negative 150 85
Unknown 181
 ‡10% immunoreactive neoplastic cells.
TABLE 2. SN and non-SN characteristics of 357 invasive
breast cancer patients with a positive SN and subsequent
axillary lymph node dissection
Feature No. %
SN
Total number of SNs 571
Mean number of SNs 1.6
Total number of positive SNs 419
Mean diameter SN metastases 4.7 mm
AJCC classiﬁcation of SN metastatic size
ITC 24 7
Micrometastasis 112 31
Macrometastasis 221 62
Extracapsular extension
No 257 72
Yes 100 28
Microanatomic location
Subcapsular 167 47
Parenchymal 11 3
Combined 40 11
Extensive 139 39
Mean penetrative depth 2.9 mm
Non-SNs
Total number of non-SNs 4939
Mean number of non-SNs (range) 14 (5–38)
Total number of positive non-SNs 474
Total number of negative non-SNs 4465
Size of non-SN metastases
ITC 3 2
Micrometastases 33 24
Macrometastases 100 74
TABLE 3. Comparison of categorical clinicopathological
and SN characteristics in invasive breast cancer patients
without and with non-SN metastases by Pearson chi-square
test
Without non-SN
metastases
With non-SN
metastases P value
Feature No (%) No (%)
Total 221 (62) 136 (38)
Histological subtype 0.914
Ductal 183 (51) 115 (32)
Lobular 22 (6) 14 (4)
Others 16 (5) 7 (2)
Histological grade (B&R) 0.798
ER positive 198 (56) 124 (35) 0.715
Negative 22 (6) 12 (3)
PR positive 179 (50) 106 (30) 0.589
Negative 41 (12) 29 (8)
HER-2/neu positive 16 (9) 10 (6) 0.670
Negative 83 (47) 67 (38)
No. of SN 0.246
1 131 (37) 89 (25)
>1 90 (25) 47 (13)
No. of involved SN 0.050
1 198 (55) 112 (31)
>1 23 (6) 24 (7)
AJCC SN metastases <0.001
ITC 21 (6) 3 (1)
Micrometastasis 86 (24) 26 (7)
Macrometastasis 114 (32) 107 (30)
Extracapsular extension <0.001
No 175 (49) 82 (23)
Yes 46 (13) 54 (15)
Microanatomic
location SN metastases
<0.001
Subcapsular 126 (35) 41 (11)
Combined 23 (6) 17 (5)
Parenchymal 8 (2) 3 (1)
Extensive 64 (18) 75 (21)
Multifocality 0.087
No 176 (49) 118 (33)
Yes 45 (13) 18 (5)
TABLE 4. Comparison of continuous clinicopathological
and SN characteristics in invasive breast cancer patients
without and with non-SN metastases by Mann–Whitney U-
test
Without non-SN
metastases
With non-SN
metastases P value
Feature
Total no. (%) 221 (62) 136 (38)
Age (years, mean) 54 53 0.249
Primary tumor
diameter, cm (mean)
2.3 2.5 0.019
MAI, 2mm
2 (mean) 13 12 0.693
SN tumor diameter,
mm (mean)
3.6 6.5 <0.001
SN tumor penetrative
depth, mm (mean)
2.2 3.9 <0.001
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other classic variables (age, histological subtype and
grade, steroid receptor and HER-2/neu status, MAI)
of the primary tumor correlated signiﬁcantly with
non-SN involvement.
The primary tumor features histological grade and
diameter were associated with multiple SN tumor
deposits (P = 0.03 and 0.05, respectively).
Frequency of non-SN metastases in patients with
SN ITC (N = 24), micro- (N = 112) and macrom-
etastases (N = 221) was 12.5%, 23%, and 48%,
respectively (P < 0.001, Fig. 3). Of those three pa-
tients with SN ITC and involved non-SNs, two had a
non-SN micro- and one had a non-SN macrometas-
tasis. One of these ITC was located in the paren-
chyma, the other two patients had a subcapsular
location. Two of these three patients with SN ITC
and non-SN involvement showed multiple small cell
clusters and single cells in the SN.
The microanatomic localization of SN metastatic
depositscorrelatedwithnon-SNinvolvement.Patients
with subcapsular (N = 167), combined subcapsular
and parenchymal (N = 40), parenchymal (N = 11)
and extensive (N = 139) tumor deposits showed non-
SNinvolvementin25%,42%,27%,and54%ofcases,
respectively (Table 3). Morphometrically assessed
penetrativedepthofSNmetastaseswasalsoassociated
with non-SN involvement. Frequency of non-SN
metastases in patients with a SN tumor penetrative
depth <0.155 mm (N = 29), 0.155–2.7 mm
(N = 181) and >2.7 mm (N = 147) was 10%, 28%,
and 56%, respectively (P < 0.001, Table 5). In ROC
analysis, diameter (AUC = 0.686) and the penetra-
tive depth (AUC = 0.680) of the SN tumor deposit
had comparable discriminative value (Fig. 4).
In multivariate analysis, SN tumor diameter
(P = 0.032) and SN tumor penetrative depth
(<0.155 mm versus 0.155–2.7 mm versus >2.7 mm)
(P = 0.015) were signiﬁcant in predicting non-SN
involvement. Cutoff values were interactively statisti-
callyasthosebestdiscriminatingbetweenlowandhigh
risk of non-SN metastases. Risk stratiﬁcation by
combining these features identiﬁed a low-risk group,
an intermediate-risk group, and a high risk group for
non-SN metastases with frequency of non-SN metas-
tases in 11%, 29%, and 56% of patients, respectively
(Table 6). Frequencies of non-SN involvement in pa-
tients with SN micrometastases and a subcapsular
(N = 91), combined subcapsular and parenchymal
(N = 15), and parenchymal location (N = 6) were
21%,40%,and17%,respectively.Frequenciesofnon-
SN involvement in patients with SN macrometastases
and a subcapsular (N = 54), combined subcapsular
and parenchymal (N = 25), parenchymal (N =4 )
and extensive location (N = 138) were 39%, 44%,
25%, and 54%, respectively.
FIG. 3. Flow chart showing distribution of SN AJCC classiﬁca-
tion according to non-SN involvement.
TABLE 5. Predictive value of penetrative depth of SN
metastases for non-SN involvement in patients with invasive
breast cancer
SN penetrative
depth (mm) N
No. of patients with
non-SN involvement (%)
<0.155 29 3 (10)
0.155–2.7 181 51 (28)
>2.7 147 82 (56)
FIG. 4. ROC curves showing the sensitivity and speciﬁcity of SN
tumor diameter and penetrative depth as predictors of non-SN
involvement. The larger the area below the curve, the more accu-
rate the prediction of non-SN involvement (P < 0.001).
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The lymphatic spread of breast cancer cells has
been shown to follow an orderly progression via the
SN to non-SNs, which implies that the risk of spread
of tumor from the SN to the non-SN may depend on
the extent of SN involvement. While many studies
have focused on the maximal diameter of the meta-
static tumor deposit
22, 23 we investigated the micro-
anatomic location and the penetrative depth of the
metastatic deposits as a putative predictor of non-SN
involvement. This was based on the concept that
within the SN, tumor cells also follow an orderly
route, arriving in the subcapsular sinuses through an
afferent lymph vessel. Later, there is subcapsular
outgrowth of malignant cells in the marginal sinuses
and into the cortical parenchyma. Finally, these cells
extend to the deeper zones of the lymph node
parenchyma, frequently following the medullary si-
nuses to efferent lymph vessels.
24 Consistent with this
concept we found that the microanatomic location,
the size, and the penetrative depth of SN tumor
deposits were correlated signiﬁcantly with non-SN
involvement. This ﬁnding is consistent with recent
melanoma studies. Startz et al.
11 proposed a micro-
morphometric classiﬁcation, based on the depth of
the metastasis from the capsule and the number of 1-
mm slices containing melanoma. This classiﬁcation
was a highly signiﬁcant predictor for distant metas-
tases and overall survival. Dewar et al.
13 also re-
corded that the microanatomic location of melanoma
SN metastases predicts non-SN involvement, and
proposed that it would be possible to safely avoid a
lymph node dissection in patients with subcapsular
deposits only. Indeed, subcapsular location and small
tumor penetrative depth correlated with less non-SN
involvement in our breast cancer study, although no
subgroup of patients could be selected without non-
SN involvement.
The measurement of the SN tumor penetrative
depth was diﬃcult in many cases, especially in case of
extensive tumor deposits. In these cases the tumor
deposits frequently extended beyond the center of the
lymph node, making it diﬃcult to determine which
edge of the SN capsule should be used to measure the
tumor penetrative depth. Similar diﬃculties were
encountered when the SN had a lobulated outline.
Further studies which more rigorously deﬁne the tu-
mor penetrative depth may strengthen its predictive
power and reproducibility.
In conclusion, patients with breast carcinoma and
SN involvement can be stratiﬁed into subgroups at
signiﬁcantly diﬀerent risk for non-SN involvement,
according to microanatomic localization of the SN
metastatic deposits and penetrative depth into the
SN. However, based on these features no subgroup of
patients could be selected without non-SN involve-
ment.
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